$4.59
+0.27 (+6.25%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where AQST is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
9 interventional · 6 with posted results
Held by 14 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, Balyasny Asset Management L.P., CITADEL ADVISORS LLC, JANE STREET GROUP, LLC, RENAISSANCE TECHNOLOGIES LLC, +9 more) · FINRA short interest 8.9 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 2 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of DESF in Pediatric SubjectsNCT07703982CmaxOpen-label · Treatment | Phase 1 | Completed | Drug: DESF | Allergic Reaction | 32 | 2025-03-14actual | 2026-07-15 |
| Pharmacokinetics Study of DESF in Adults With Oral Allergy SyndromeNCT06527937CmaxRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: DESF, Epinephrine Injection | Allergic Reaction | 36 | 2024-10-10actual | 2025-09-26 |
| Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With EpilepsyNCT03428360results2021-08-05Number of Subjects in the Safety Analysis Set With at Least 1 Treatment-emergent Adverse Event (TEAE)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category | Epilepsy | 149 | 2020-06-25actual | 2021-08-05 |
| Pharmacokinetics and Safety Study of Diazepam Buccal Film (DBF) in Pediatric Subjects With EpilepsyNCT03222349results2021-05-26Area Under the Concentration Time Curve (AUC) 0 to 4 Hours Post-doseNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Diazepam Buccal Film | Epilepsy | 24 | 2020-01-28actual | 2021-05-26 |
| Diazepam Buccal Film (DBF) - Diastat Rectal Gel (DRG) Crossover StudyNCT03953820results2020-08-18AUC 0-tRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Diazepam Buccal Film, Diastat® Rectal Gel (Valeant Pharmaceuticals USA) | Epilepsy | 31 | 2019-07-31actual | 2020-08-18 |
| Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Sclerosis (ALS)NCT03679975results2020-08-10Number of Participants Categorized by Differences From Baseline in Penetration Aspiration Scale (PAS) - Sum of Scores MethodOpen-label · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The study is no longer required | Drug: Riluzole Oral Soluble film (ROSF) 50 mg | Amyotrophic Lateral Sclerosis | 9 | 2018-09-26actual | 2020-08-18 |
| Study of Diazepam Buccal Film Administered in the Interictal and in the Ictal-Periictal States to Adults With EpilepsyNCT03179891results2020-09-18Tmax Pharmacokinetic EndPointsNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Diazepam Buccal Film 12.5 mg | Epilepsy | 35 | 2018-07-25actual | 2020-09-18 |
| Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral SclerosisNCT03457753Change from baseline in NCI-CTC score at week 12Open-label · Other | Phase 2 | Withdrawnsponsor's stated reason: The Sponsor stopped the study due to a change in study plans | Drug: Riluzole Oral Soluble Film | ALS | 0 | 2018-03-27actual | 2019-05-13 |
| Three-way Crossover Study Comparing Ondansetron ODFS Administered With and Without Water to Zofran ODT Without WaterNCT01220167results2020-08-18CmaxRandomized · Open-label · Other | Phase 1 | Completed | Drug: Ondansetron 8 mg ODFS without water, Ondansetron 8 mg ODFS with water, Zofran ODT (ondansetron 8 mg) without water | Healthy Participants | 18 | Aug 2008actual | 2020-08-18 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19